Bar Harbor BioTechnology this week released its XenoQ assays, which are designed to quantitatate human tumor response in xenograft experiments.
The assays combine quantitative PCR primer design with Bar Harbor's Global Pattern Recognition-analysis methodology, which allows researchers to "accurately measure gene expression and gene copy number variation in human cancer cells without cross-reactivity of other species," the company said in a statement.
Researchers can use the assays to measure how a drug affects a tumor and detect if there is a correlation of dosage to gene copy-number variations found in a patient's cells, the company said.
Bar Harbor has signed an agreement with Lonza to distribute the XenoQ assays. The deal expands a distribution agreement between the firms that began in 2008 that made Lonza the exclusive global distributor of the company's StellArray Gene Expression System, which combines qPCR arrays with the GPR software.
In addition to XenoQ, Lonza will now distribute Bar Harbor's GPR 2.0 and Custom Plate Designer products under the expanded agreement.